Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial
European Journal of Heart Failure · 01.04.2024 · 26 (4) · 900-909
DOI: 10.1002/ejhf.3221 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Heart Failure, online erschienen am 01.04.2024. Verfasst von Naveed Sattar und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC), Glasgow, UK. Hauptthemen laut MEDLINE: Body Mass Index, Sodium-Glucose Transporter 2 Inhibitors, Glucosides, Benzhydryl Compounds. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
Aims
Both low and high body mass index (BMI) are associated with poor heart failure outcomes. Whether BMI modifies benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) requires further investigation. Methods and results Using EMPEROR-Preserved data, the effects of empagliflozin versus placebo on the risks for the primary outcome (hospitalization for heart failure [HHF] or cardiovascular [CV] death), change in estimated glomerular filtration rate (eGFR) slopes, change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), and secondary outcomes across baseline BMI categories (<25 kg/m2, 25 to <30 kg/m2, 30 to <35 kg/m2, 35 to <40 kg/m2 and ≥40 kg/m2) were examined, and a meta-analysis conducted with DELIVER. Forty-five percent had a BMI of ≥30 kg/m2. For the primary outcome, there was a consistent treatment effect of empagliflozin versus placebo across the BMI categories with no formal interaction (p trend = 0.19) by BMI categories. There was also no difference in the effects on secondary outcomes including total HHF (p trend = 0.19), CV death (p trend = 0.20), or eGFR slope with slower declines with empagliflozin regardless of BMI (range 1.12–1.71 ml/min/1.73 m2 relative to placebo, p trend = 0.85 for interaction), though there was no overall impact on the composite renal endpoint. The difference in weight change between empagliflozin and placebo was −0.59, −1.48, −1.54, −0.87, and − 2.67 kg in the lowest to highest BMI categories (p trend = 0.016 for interaction). A meta-analysis of data from EMPEROR-Preserved and DELIVER showed a consistent effect of SGLT2i versus placebo across BMI categories for the outcome of HHF or CV death. There was a trend toward greater absolute KCCQ-CSS benefit at 32 weeks with empagliflozin at higher BMIs (p = 0.08).
Conclusions
Empagliflozin treatment resulted in broadly consistent cardiac effects across the range of BMI in patients with HFpEF. SGLT2i treatment yields benefit in patients with HFpEF regardless of baseline BMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cardiovascular and Metabolic Health, University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC), Glasgow, UK.
- Baylor Scott and White Research Institute, Dallas TX and University of Mississippi, Jackson, MS, USA.
- Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA.
- Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
- Université de Lorraine, Inserm, Centre d'Investigations Cliniques, -Plurithématique 14-33 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
- National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
ORCID-Profile: Naveed Sattar
Förderung
- British Heart Foundation
Zitieren
APA
Sattar, N., Butler, J., Lee, M. M. Y., Harrington, J., Sharma, A., Zannad, F., Filippatos, G., Verma, S., Januzzi, J. L., Ferreira, J. P., Pocock, S. J., Pfarr, E., Ofstad, A. P., Brueckmann, M., Packer, M., & Anker, S. D. (2024). Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial. European Journal of Heart Failure, 26(4), 900-909. https://doi.org/10.1002/ejhf.3221
Vancouver
Sattar N, Butler J, Lee MMY, Harrington J, Sharma A, Zannad F, et al. Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial. European Journal of Heart Failure. 2024;26(4):900-909. doi:10.1002/ejhf.3221
BibTeX
@article{Sattar2024,
author = {Sattar, Naveed and Butler, Javed and Lee, Matthew M Y and Harrington, Josephine and Sharma, Abhinav and Zannad, Faiez and Filippatos, Gerasimos and Verma, Subodh and Januzzi, James L and Ferreira, João Pedro and Pocock, Stuart J and Pfarr, Egon and Ofstad, Anne P and Brueckmann, Martina and Packer, Milton and Anker, Stefan D},
title = {Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial},
journal = {European Journal of Heart Failure},
year = {2024},
volume = {26},
number = {4},
pages = {900--909},
doi = {10.1002/ejhf.3221}
}
EUVIMED